Skip to content
Screener

Theravance Biopharma TBPH Price / earnings

Price / earnings at other companies

Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
135.3×+50.1×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
1.4×-7.3×
Royalty Pharma logo
Royalty PharmaRPRX
30.5×+15.6×
United Therapeutics logo
United TherapeuticsUTHR
17.5×+7.0×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
14.5×-175×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
6.9×-11.0×

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$877.45M+53.9%
Enterprise value$629.86M+88.3%
P/S8×+0.6×

Profitability

See full
Gross margin60.8%—
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Calculated from Theravance Biopharma’s reported figures.

market cap/net income=7.3×

Based on the most recent quarter.

The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 9:00 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056760

FAQ

What is Theravance Biopharma's price / earnings?
Theravance Biopharma (TBPH) reported price / earnings of 7.3× in Q1 2026.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.

Ask your AI about Theravance Biopharma's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude